by Ayomide Banjo | May 11, 2024 | Uncategorized
Lung cancer, often detected at late stages, continues to be a leading cause of mortality worldwide. Smoking is a well-known contributor to most forms of lung cancer, however, the causes of lung adenocarcinoma remains elusive, despite it being the more prevalent form...
by sanhitamehta | Apr 27, 2024 | Uncategorized
We are glad to announce that we have secured investment from Genesis Ventures. This pre-seed funding round, led by Genesis Ventures, signifies a significant milestone in our journey towards transforming cancer diagnostics. 1. Critical Need for Lung Cancer Testing Lung...
by sanhitamehta | Apr 15, 2024 | Uncategorized
Recognising the critical importance of early detection, the NHS has initiated a pioneering lung screening programme aimed at identifying lung cancer in its earliest stages among those at highest risk. This initiative represents a proactive approach to healthcare that...
by sanhitamehta | Apr 12, 2024 | Uncategorized
Currently, several models are used to pre-screen patients for lung cancer and to determine eligibility for CT scans. However, most of these models are designed specifically for smokers and cannot accurately predict the risk of lung cancer in non-smokers. Furthermore,...
by sanhitamehta | Mar 21, 2024 | Uncategorized
We are happy to share that we have been recognised by Cancer Research Horizons during the 2024 Innovation & Entrepreneurship Awards! This award focused on celebrating the UK’s most innovative and enterprising efforts in Oncology Research. Averywell was...
by sanhitamehta | Sep 20, 2023 | News&blogs, Uncategorized
We are happy to share that Averywell was listed as a finalist at the 2023 BioCap Conference held by Bionow. Bionow is a non-profit hoping to support the biomedical, pharma and life sciences sectors across North England. They aim to provide the tools and support for...
